Home NDC 55513-742-10 PARSABIV
Product NDC 55513-742
Requested package NDC 55513-742-10
11-digit product format 555130742
Labeler code 55513
Product ID 55513-742_52286976-a97a-4b77-b678-f40ab5aa7133
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name etelcalcetide
Dosage form INJECTION, SOLUTION
Route INTRAVENOUS
Labeler Amgen, Inc
Application NDA208325
Marketing category NDA
Marketing start 2017-04-03
Substance ETELCALCETIDE HYDROCHLORIDE
Active strength 10 mg/2mL
Pharmacologic classes Calcium-sensing Receptor Agonist [EPC], Increased Calcium-sensing Receptor Sensitivity [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N208325-001 PARSABIV ETELCALCETIDE 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 N208325-002 PARSABIV ETELCALCETIDE 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 N208325-003 PARSABIV ETELCALCETIDE 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07
Orange Book patents# Current patent rows page 1 of 1 · 24 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 N208325-003 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-003 9278995 2030-07-29 Drug substance 2017-06-01 N208325-003 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-003 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-003 10344765 2034-06-27 Drug product 2019-07-19 N208325-003 11162500 2034-06-27 Drug product 2021-11-12 N208325-003 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-003 9820938 2034-06-27 Drug product 2017-11-29
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 129 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-08-18 06:07:40 2026-07 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 301d65b070ca…
Observed Orange Book patent history# Patent history page 1 of 24 · 924 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-08-18 06:07:40 2026-07 N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 caaa826d4ba7…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 54 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base PARSABIV
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength ETELCALCETIDE HYDROCHLORIDE 10 mg/2mL
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 72PT5993DU Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 6 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1876127 Internal RxNorm lookup 1876132 Internal RxNorm lookup 1876135 Internal RxNorm lookup 1876136 Internal RxNorm lookup 1876137 Internal RxNorm lookup 1876138 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 55513-742-01 PARSABIV 2 mL in 1 VIAL, SINGLE-DOSE INJECTION, SOLUTION 2 15 55513-742-10 PARSABIV 10 in 1 CARTON INJECTION, SOLUTION 10 15 55513-742-20 PARSABIV 10 in 1 CARTON INJECTION, SOLUTION 10 15
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 55513-742 PARSABIV (ETELCALCETIDE) INJECTION, SOLUTION [AMGEN INC] 13 Current NDC, Legacy NDC, 3 package rows 20220626_cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Marketing end Sample Exclude flag Status 55513-742-10 55513074210 10 VIAL, SINGLE-DOSE in 1 CARTON (55513-742-10) / 2 mL in 1 VIAL, SINGLE-DOSE (55513-742-01) 2017-04-03 0000-00-00 No No Current